kıbrıs ingiltere londra lefkoşa
DOLAR
8,3756
EURO
9,9753
STERLIN
11,6655
BITCOIN
$39.567,80
Adana Adıyaman Afyon Ağrı Aksaray Amasya Ankara Antalya Ardahan Artvin Aydın Balıkesir Bartın Batman Bayburt Bilecik Bingöl Bitlis Bolu Burdur Bursa Çanakkale Çankırı Çorum Denizli Diyarbakır Düzce Edirne Elazığ Erzincan Erzurum Eskişehir Gaziantep Giresun Gümüşhane Hakkari Hatay Iğdır Isparta İstanbul İzmir K.Maraş Karabük Karaman Kars Kastamonu Kayseri Kırıkkale Kırklareli Kırşehir Kilis Kocaeli Konya Kütahya Malatya Manisa Mardin Mersin Muğla Muş Nevşehir Niğde Ordu Osmaniye Rize Sakarya Samsun Siirt Sinop Sivas Şanlıurfa Şırnak Tekirdağ Tokat Trabzon Tunceli Uşak Van Yalova Yozgat Zonguldak
LONDRA
Az bulutlu
22°C
LONDRA
22°C
Az bulutlu
Salı Hafif yağmur
24°C
Çarşamba Hafif yağmur
="http://www.w3.org/2000/svg" viewBox="0 0 300 300" enable-background="new 0 0 300 300">
18°C
Perşembe Hafif yağmur
="http://www.w3.org/2000/svg" viewBox="0 0 300 300" enable-background="new 0 0 300 300">
20°C
Cuma hafif yağmur
="http://www.w3.org/2000/svg" viewBox="0 0 300 300" enable-background="new 0 0 300 300">
19°C

Trial results suggest Novavax jab 100% effective in protecting against  severe disease

Trial results suggest Novavax jab 100% effective in protecting against  severe disease
14.06.2021
0
A+
A-

Novavax has said its Covid-19 vaccine is 100% effective in protecting against “moderate and severe disease” following its phase three trial results.

The American biotechnology company said the trial had shown its vaccine was also 93% effective against circulating variants of concern and variants of interest, and 91% effective in protecting high-risk populations.

The trial, which involved 29,960 participants across 119 sites across the US and Mexico, showed 90.4% efficacy overall.

The study placed an emphasis on having participants that represented communities and demographics most impacted by the disease.

Within the group, 77 people tested positive for Covid-19, 63 were on a placebo and 14 had received the vaccine.

All of the cases in the vaccinated group were defined as “mild” while 10 “moderate” cases and four “severe” cases were observed among those who had been given the placebo.

Preliminary safety data from the study also showed “generally mild and moderate” pain and tenderness around the injection site, as well as fatigue, muscle pain and headache were the most common symptoms in participants.

Gregory Glenn, president of research and development at Novavax, said: “Our vaccine will be a critical part of the solution to Covid-19 and we are grateful to the study participants and trial staff who made this study possible, as well as our supporters, including the US government.”

The company remains on track to be able to manufacture 100 million vaccine doses a month by the end of September and 150 million doses by the end of the year, once it receives regulatory approvals.

Yorumlar

Henüz yorum yapılmamış. İlk yorumu yukarıdaki form aracılığıyla siz yapabilirsiniz.